Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody

被引：17
|
作者：
Lacouture, ME [1 ]
Baron, JM
Jani, AB
Laumann, AE
Soltani, K
机构：
[1] Univ Chicago, Pritzker Sch Med, Dept Med, Dermatol Sect, Chicago, IL 60637 USA
[2] Univ Chicago, Pritzker Sch Med, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA
[3] Univ Chicago, Pritzker Sch Med, Dept Radiat Oncol, Chicago, IL 60637 USA
来源：
CLINICAL AND EXPERIMENTAL DERMATOLOGY | 2005年 / 30卷 / 01期
关键词：
D O I：
10.1111/j.1365-2230.2004.01659.x
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Primary cutaneous B cell lymphomas have a high recurrence rate after treatment with surgery and/or local radiation therapy. Two men are described in whom radiotherapy-relapsing cutaneous B-cell lymphomas were successfully treated with the monoclonal anti-CD20 antibody rituximab. Both patients had a complete response with no recurrence at follow-up at 17 and 24 months for the large B-cell lymphoma of the leg and the follicle centre cell lymphoma, respectively. These are two of the few cases in the literature showing that rituximab is an effective and well-tolerated treatment for radiotherapy-relapsing primary cutaneous B cell lymphoma.
引用
收藏
页码：46 / 48
页数：3
相关论文
共 50 条
12345